Auckland Cancer Society Research Centre Special Seminar - Dr Jilly Evan Event as iCalendar

24 November 2017

2 - 3pm

Venue: CBR seminar room 501-505

Location: FMHS, 85 Park Road Grafton

Host: Auckland Cancer Society Research Centre

“Potential novel therapies for Lymphangioleiomyomatosis (LAM), a rare lung disease of women” by Jilly Evans.

Jilly Evans, PhD is a world authority in the eicosanoid field (molecules that control inflammation and immunity).

Whilst working for international pharmaceutical company Merck and Co, she played a key role in the development of Singulair, a drug with proven success in alleviating the symptoms of asthma, as well as the drugs Arcoxia and Vioxx, used for the treatment of arthritis.

Since leaving Merck, Jilly has co-founded Amira Pharmaceuticals, a company developing anti-inflammatory and anti-fibrotic therapies, which was acquired by Bristol Myers Squibb in 2011. She then went on to become chief scientific officer and co-founder of San Diego US-based biopharmaceutical company PharmAkea (www.pharmakea.com).

Abstract: Lymphangioleiomyomatosis (LAM) is a rare devastating lung disease of women. The origin of LAM cells is still unknown but once formed these metastatic smooth muscle-like cells are transported in the lymphatics to the lung where they proliferate resulting in lung tissue destruction, cyst formation and inability to breathe. 

About 15 years ago it was shown that LAM patients have mutations in the suppressor proteins TSC2 or TSC1 resulting in highly activated mTOR signaling in both lung lesions and kidney angiolipomas. The mTOR inhibitor rapamycin has been shown to slow the loss of lung function in 50% of LAM patients. However, there is no therapy for the other 50% of patients and the only intervention is lung transplantation.

In this seminar, Jilly will discuss potential novel therapies that may be additive with rapamycin or may provide monotherapy in the rapamycin non-responsive patients.

Open to staff and students.